Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1389786

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1389786

Antibody Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 246 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

Fairfield Market Research, a renowned market research firm, has released a comprehensive report on the Antibody Testing market, forecasting robust growth in the sector. The worldwide revenue generated from the antibody testing market amounted to US$ 7.99 billion in 2024. This growth trajectory is expected to drive the market to a valuation of approximately US$ 17.1 billion by the end of 2031.

Driving Factors for Antibody Testing Market Growth

Development of Disease-Specific Biomarkers and Lab Automation: Recent advancements in disease biomarker development have opened up new opportunities in the antibody testing market. Innovations in proteomics, genomics, and metabolomics have enabled researchers to identify specific genetic markers associated with various diseases, particularly cancer and its subtypes. Diagnostic tools based on these biomarkers are expected to fuel market expansion, providing accurate, cost-effective, and efficient solutions for healthcare professionals.

Laboratory automation is also playing a crucial role in driving market growth. The increasing prevalence of chronic diseases, a growing aging population, and rising global population have boosted the demand for diagnostic tests. Automation in laboratories is essential to deliver rapid results without compromising quality, making it imperative for the adoption of antibody-based test kits.

Challenges Impacting Market Growth

Regulatory Impositions and Limitations of Current Diagnostics: Regulatory frameworks imposed by governments to ensure the quality and safety of pharmaceutical and medical devices can hinder market expansion. Compliance with these regulations can be particularly challenging for small market players, resulting in delays in product introductions.

Prolonged trial periods and the associated costs for medical devices can also present obstacles to market growth. The regulatory landscape needs to balance quality assurance with the financial goals of pharmaceutical and medical device companies to foster innovation.

Country-wise Insights

Booming U.S. Market: The U.S. market held a dominant market share of approximately 94.4% in North America in 2022. Rising autoimmune disease cases and government initiatives to promote health insurance programs are expected to drive the market's growth in the U.S. over the forecast period.

Lucrative German Market: Germany has witnessed market growth, particularly due to the emergence of COVID-19. The government's decision to reimburse COVID-19 antibody tests has led to increased accessibility. This support has contributed to the adoption of antibody test kits within the country.

Emerging Chinese Market: China's market has been expanding due to its focus on research and development for innovative antibody tests. Chinese R&D firms are concentrating on developing biospecific antibody tests, contributing to the market's growth.

Competitive Landscape

Key players in the market are prioritizing product innovation through technological advancements and product availability in various dimensions. Institutional-level research is being conducted for continuous product evolution. Major competitors are also focusing on market penetration through alternate sales channels.

Key Market Players:

  • Thermo Fisher Scientific
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Beckton, Dickinson and Company
  • F. Hoffmann-La Roche
  • Agilent Technologies
  • DiaSorin
  • Zeus Scientific
  • Abcam PLC
  • Trinity Biotech
  • Werfen (Biokit)
  • Promega
  • BioLegend
  • Meridian Bioscience
  • Bio-Techne (R&D Systems)

Key Segments Covered in Antibody Testing Industry Research

Product:

  • Serological Test Kits

Serological Assay Test Kits

Serological Rapid Assay Kits

  • Immunoglobulin Kits

Immunoglobulin Assay Test Kits

Immunoglobulin Rapid Assay Kits

  • Lateral Flow Assay Kits

Lateral Flow Assay Test Kits

Lateral Flow Rapid Assay Kits

  • Chemical and Reagents
  • Consumables

Indication:

  • Pregnancy
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Infectious Diseases
  • Oncology
  • Endocrine Diseases
  • Diabetes
  • Others

End User:

  • Hospitals
  • Academic and Research Institutes
  • Diagnostic Laboratories
  • Biopharmaceutical Companies
  • Homecare Settings

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Antibody Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Antibody Testing Market Outlook, 2018 - 2031

  • 3.1. Global Antibody Testing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Serological Test Kits
        • 3.1.1.1.1. Serological Assay Test Kits
        • 3.1.1.1.2. Serological Rapid Assay Kits
      • 3.1.1.2. Immunoglobulin Kits
        • 3.1.1.2.1. Immunoglobulin Assay Test Kits
        • 3.1.1.2.2. Immunoglobulin Rapid Assay Kits
      • 3.1.1.3. Lateral Flow Assay Kits
        • 3.1.1.3.1. Lateral Flow Assay Test Kits
        • 3.1.1.3.2. Lateral Flow Rapid Assay Kits
      • 3.1.1.4. Chemical and Reagents
      • 3.1.1.5. Consumables
  • 3.2. Global Antibody Testing Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Pregnancy
      • 3.2.1.2. Cardiovascular Diseases
      • 3.2.1.3. Autoimmune Diseases
      • 3.2.1.4. Infectious Diseases
      • 3.2.1.5. Oncology
      • 3.2.1.6. Endocrine Diseases
      • 3.2.1.7. Diabetes
      • 3.2.1.8. Others
  • 3.3. Global Antibody Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Academic and Research Institutes
      • 3.3.1.3. Diagnostic Laboratories
      • 3.3.1.4. Biopharmaceutical Companies
      • 3.3.1.5. Homecare Settings
  • 3.4. Global Antibody Testing Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Antibody Testing Market Outlook, 2018 - 2031

  • 4.1. North America Antibody Testing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Serological Test Kits
        • 4.1.1.1.1. Serological Assay Test Kits
        • 4.1.1.1.2. Serological Rapid Assay Kits
      • 4.1.1.2. Immunoglobulin Kits
        • 4.1.1.2.1. Immunoglobulin Assay Test Kits
        • 4.1.1.2.2. Immunoglobulin Rapid Assay Kits
      • 4.1.1.3. Lateral Flow Assay Kits
        • 4.1.1.3.1. Lateral Flow Assay Test Kits
        • 4.1.1.3.2. Lateral Flow Rapid Assay Kits
      • 4.1.1.4. Chemical and Reagents
      • 4.1.1.5. Consumables
  • 4.2. North America Antibody Testing Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Pregnancy
      • 4.2.1.2. Cardiovascular Diseases
      • 4.2.1.3. Autoimmune Diseases
      • 4.2.1.4. Infectious Diseases
      • 4.2.1.5. Oncology
      • 4.2.1.6. Endocrine Diseases
      • 4.2.1.7. Diabetes
      • 4.2.1.8. Others
  • 4.3. North America Antibody Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Academic and Research Institutes
      • 4.3.1.3. Diagnostic Laboratories
      • 4.3.1.4. Biopharmaceutical Companies
      • 4.3.1.5. Homecare Settings
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Antibody Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Antibody Testing Market Outlook, 2018 - 2031

  • 5.1. Europe Antibody Testing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Serological Test Kits
        • 5.1.1.1.1. Serological Assay Test Kits
        • 5.1.1.1.2. Serological Rapid Assay Kits
      • 5.1.1.2. Immunoglobulin Kits
        • 5.1.1.2.1. Immunoglobulin Assay Test Kits
        • 5.1.1.2.2. Immunoglobulin Rapid Assay Kits
      • 5.1.1.3. Lateral Flow Assay Kits
        • 5.1.1.3.1. Lateral Flow Assay Test Kits
        • 5.1.1.3.2. Lateral Flow Rapid Assay Kits
      • 5.1.1.4. Chemical and Reagents
      • 5.1.1.5. Consumables
  • 5.2. Europe Antibody Testing Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Pregnancy
      • 5.2.1.2. Cardiovascular Diseases
      • 5.2.1.3. Autoimmune Diseases
      • 5.2.1.4. Infectious Diseases
      • 5.2.1.5. Oncology
      • 5.2.1.6. Endocrine Diseases
      • 5.2.1.7. Diabetes
      • 5.2.1.8. Others
  • 5.3. Europe Antibody Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Academic and Research Institutes
      • 5.3.1.3. Diagnostic Laboratories
      • 5.3.1.4. Biopharmaceutical Companies
      • 5.3.1.5. Homecare Settings
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Antibody Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Antibody Testing Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Antibody Testing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Serological Test Kits
        • 6.1.1.1.1. Serological Assay Test Kits
        • 6.1.1.1.2. Serological Rapid Assay Kits
      • 6.1.1.2. Immunoglobulin Kits
        • 6.1.1.2.1. Immunoglobulin Assay Test Kits
        • 6.1.1.2.2. Immunoglobulin Rapid Assay Kits
      • 6.1.1.3. Lateral Flow Assay Kits
        • 6.1.1.3.1. Lateral Flow Assay Test Kits
        • 6.1.1.3.2. Lateral Flow Rapid Assay Kits
      • 6.1.1.4. Chemical and Reagents
      • 6.1.1.5. Consumables
  • 6.2. Asia Pacific Antibody Testing Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Pregnancy
      • 6.2.1.2. Cardiovascular Diseases
      • 6.2.1.3. Autoimmune Diseases
      • 6.2.1.4. Infectious Diseases
      • 6.2.1.5. Oncology
      • 6.2.1.6. Endocrine Diseases
      • 6.2.1.7. Diabetes
      • 6.2.1.8. Others
  • 6.3. Asia Pacific Antibody Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Academic and Research Institutes
      • 6.3.1.3. Diagnostic Laboratories
      • 6.3.1.4. Biopharmaceutical Companies
      • 6.3.1.5. Homecare Settings
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Antibody Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Antibody Testing Market Outlook, 2018 - 2031

  • 7.1. Latin America Antibody Testing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Serological Test Kits
        • 7.1.1.1.1. Serological Assay Test Kits
        • 7.1.1.1.2. Serological Rapid Assay Kits
      • 7.1.1.2. Immunoglobulin Kits
        • 7.1.1.2.1. Immunoglobulin Assay Test Kits
        • 7.1.1.2.2. Immunoglobulin Rapid Assay Kits
      • 7.1.1.3. Lateral Flow Assay Kits
        • 7.1.1.3.1. Lateral Flow Assay Test Kits
        • 7.1.1.3.2. Lateral Flow Rapid Assay Kits
      • 7.1.1.4. Chemical and Reagents
      • 7.1.1.5. Consumables
  • 7.2. Latin America Antibody Testing Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Pregnancy
      • 7.2.1.2. Cardiovascular Diseases
      • 7.2.1.3. Autoimmune Diseases
      • 7.2.1.4. Infectious Diseases
      • 7.2.1.5. Oncology
      • 7.2.1.6. Endocrine Diseases
      • 7.2.1.7. Diabetes
      • 7.2.1.8. Others
  • 7.3. Latin America Antibody Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Academic and Research Institutes
      • 7.3.1.3. Diagnostic Laboratories
      • 7.3.1.4. Biopharmaceutical Companies
      • 7.3.1.5. Homecare Settings
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Antibody Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Antibody Testing Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Antibody Testing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Serological Test Kits
        • 8.1.1.1.1. Serological Assay Test Kits
        • 8.1.1.1.2. Serological Rapid Assay Kits
      • 8.1.1.2. Immunoglobulin Kits
        • 8.1.1.2.1. Immunoglobulin Assay Test Kits
        • 8.1.1.2.2. Immunoglobulin Rapid Assay Kits
      • 8.1.1.3. Lateral Flow Assay Kits
        • 8.1.1.3.1. Lateral Flow Assay Test Kits
        • 8.1.1.3.2. Lateral Flow Rapid Assay Kits
      • 8.1.1.4. Chemical and Reagents
      • 8.1.1.5. Consumables
  • 8.2. Middle East & Africa Antibody Testing Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Pregnancy
      • 8.2.1.2. Cardiovascular Diseases
      • 8.2.1.3. Autoimmune Diseases
      • 8.2.1.4. Infectious Diseases
      • 8.2.1.5. Oncology
      • 8.2.1.6. Endocrine Diseases
      • 8.2.1.7. Diabetes
      • 8.2.1.8. Others
  • 8.3. Middle East & Africa Antibody Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Academic and Research Institutes
      • 8.3.1.3. Diagnostic Laboratories
      • 8.3.1.4. Biopharmaceutical Companies
      • 8.3.1.5. Homecare Settings
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Antibody Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Antibody Testing Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Antibody Testing Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Antibody Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Segment 3 vs by Indication Heat map
  • 9.2. Manufacturer vs by Indication Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Thermo Fisher Scientific.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Abbott Laboratories
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Beckton, Dickinson and Company
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. F. Hoffmann-La Roche
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Agilent Technologies
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. DiaSorin
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Zeus Scientific
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Abcam PLC
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Trinity Biotech
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Werfen (Biokit)
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Promega
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. BioLegend
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Meridian Bioscience
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Bio-Techne (R&D Systems)
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!